iNFixion Bioscience, Inc.
June 23, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Orphan and Rare Disease
Infixion Bioscience is developing first in class, FDA bound treatments for Neurofibromatosis Type 1 (NF1), a genetic disease affecting 125,000 people in the U.S. and 2.5M worldwide. Founded by NF1 parents and drug discovery experts, the team has built a fully operational lab (JLABS), top-tier advisory network, and strong in vitro proof of concept data. Infixion’s mutation agnostic ASO approach boosts neurofibromin from the functional NF1 allele, aiming to halt/reverse diverse NF1 symptoms. Supported to date by $4.3M in NIH/ DoD and NF foundation grants, Infixion has completed NIH I Corps, built several NF1 tools, executed major academic collaborations and demonstrated targeted NF1 protein increases using ASOs.
Company HQ City:
San Diego
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2018
CEO
Herb Sarnoff
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}